
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : ALX Oncology
Deal Size : $4.5 million
Deal Type : Acquisition
ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio
Details : ALX Oncology expands its pipeline with new anti-cancer drug candidates based on ScalmiBio’s platform and in combination with ALX Oncology’s lead candidate, evorpacept, a next-generation CD47 blocker designed to leverage the immune activation of broad...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $6.5 million
October 07, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : ALX Oncology
Deal Size : $4.5 million
Deal Type : Acquisition
